1 – 6 of 6
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer : Results from the Prospective, International, Observational Prostate Cancer Registry
(
- Contribution to journal › Article
-
Mark
The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells
(
- Contribution to journal › Article
-
Mark
A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome : No Evidence of Benefit, Supported by Epidemiology and In Vitro Data
(
- Contribution to journal › Article
- 2021
-
Mark
COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19) : a structured summary of a study protocol for a randomised controlled trial
(
- Contribution to journal › Letter
- 2019
-
Mark
A registry-based study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide
(
- Contribution to journal › Article
- 2017
-
Mark
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer : Extended Analysis of the Phase 3 PREVAIL Study
(
- Contribution to journal › Article